Table 5. . Cost savings of antiarrhythmic drugs when compared with ablation (non-temporal scenarios).
| Treatment | Annual medication costs/ablation procedure costs, $ | LTCO costs (including procedural complications for ablation), $ | Total costs† PPPY, $ | Cost savings‡ PPPY, $ |
|---|---|---|---|---|
| Dronedarone + ablation | 8894 | 11,273 | 20,166.89 | 19,213 |
| Amiodarone + ablation | 3986 | 10,992 | 14,977.86 | 24,402 |
| Sotalol + ablation | 6217 | 11,391 | 17,608.27 | 21,772 |
| Flecainide + ablation | 4835 | 10,079 | 14,913.71 | 24,466 |
| Propafenone + ablation | 4305 | 11,080 | 15,385.28 | 23,995 |
| Dofetilide + ablation | 10,410 | 11,780 | 22,190.19 | 17,190 |
| AADs (group) + ablation | 6441 | 10,837 | 17,277.89 | 22,102 |
| Ablation | 29,432 | 9948 | 39,380.04 |
†
Total cost is the sum of annual medication costs or ablation procedure costs and LTCO costs.
‡
Cost savings is calculated as the difference between ablation cost and the combination of each drug with ablation cost.
AAD: Antiarrhythmic drug; LTCO: Long-term clinical outcome; PPPY: Per patient per year.